3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
CNS
2
Breast
2
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
13
Sarcoma
5
Testicular Neoplasms
4
Astrocytoma
4
Wilms Tumor
3
Optic Nerve Glioma
3
Oligodendroglioma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Neuroblastoma
3
Medulloblastoma
3
Kidney Neoplasms
3
Familial ependymoma
3
Fallopian Tube Neoplasms
3
Choroid Plexus Neoplasms
3
Central Nervous System Neoplasms
3
Triple Negative Breast Neoplasms
2
Testicular Germ Cell Tumor
2
Teratoma
2
Ovarian Germ Cell Cancer
2
Osteosarcoma
2
Liver Neoplasms
2
Head and Neck Neoplasms
2
Glioma
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Alveolar Soft Part
1
Interventions
pembrolizumab
14
Specimen Handling
8
Docetaxel
8
olaparib
7
Nivolumab
7
Gemcitabine
7
Trastuzumab
6
Paclitaxel
6
rucaparib
5
Magnetic Resonance Spectroscopy
5
Early Intervention, Educational
5
Biopsy
5
Standard of Care
4
Cyclophosphamide
4
Carboplatin
4
tisotumab vedotin
3
talazoparib
3
pertuzumab
3
durvalumab
3
atezolizumab
3
Taxes
3
Surveys and Questionnaires
3
Sirolimus
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Methods
3
Irinotecan
3
Immunoglobulin G
3
Fulvestrant
3
Educational Status
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Temozolomide
×
Gynecologic
×
Clear all
NCT05417594
2026-05-05
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled